Orbimed Advisors LLC Adc Therapeutics Sa Transaction History
Orbimed Advisors LLC
- $3.21 Billion
- Q1 2025
A detailed history of Orbimed Advisors LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Orbimed Advisors LLC holds 5,968,451 shares of ADCT stock, worth $14.5 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
5,968,451
Previous 5,968,451
-0.0%
Holding current value
$14.5 Million
Previous $11.9 Million
29.15%
% of portfolio
0.26%
Previous 0.32%
Shares
3 transactions
Others Institutions Holding ADCT
# of Institutions
84Shares Held
53.9MCall Options Held
5KPut Options Held
7.6K-
Redmile Group, LLC San Francisco, CA15.7MShares$38.1 Million2.32% of portfolio
-
Prosight Management, LP Dallas, TX9.54MShares$23.2 Million4.79% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$8.64 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.02MShares$7.34 Million0.0% of portfolio
-
Platinum Investment Management LTD Sydney Australia 2000, C32.04MShares$4.95 Million0.18% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $189M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...